BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK. A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. Cancer Chemother Pharmacol. 2014;73:665-671. [PMID: 24562525 DOI: 10.1007/s00280-013-2371-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma YC, Sun H, Shi JX, Dong ZM, Li P. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget 2017;8:27471-80. [PMID: 28460467 DOI: 10.18632/oncotarget.15832] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
2 Fang YF, Geng Q. Research progress and prospects of esophageal cancer in era of precision medicine. Shijie Huaren Xiaohua Zazhi 2017; 25(32): 2829-2837 [DOI: 10.11569/wcjd.v25.i32.2829] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Wen Y, Zhao Z, Miao J, Yang Q, Gui Y, Sun M, Tian H, Jia Q, Liao D, Yang C, Du X. S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial. Medicine (Baltimore) 2017;96:e8998. [PMID: 29245275 DOI: 10.1097/MD.0000000000008998] [Reference Citation Analysis]
4 Guo S, Liu F, Liu H, Wu Y, Zhang X, Ye W, Luo G, Li Q, Chen N, Hu N, Wang B, Zhang J, Lin M, Feng H, Qiu B. A Prospective Phase II Study of Simultaneous Modulated Accelerated Radiotherapy Concurrently With CDDP/S1 for Esophageal Squamous Cell Carcinoma in the Elderly. Front Oncol 2021;11:760631. [PMID: 34900709 DOI: 10.3389/fonc.2021.760631] [Reference Citation Analysis]
5 Zhu H, Ge X, Lu Y, Zuo Y, Qin Q, Sun X, Yang M. Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. Oncol Lett 2019;17:594-602. [PMID: 30655806 DOI: 10.3892/ol.2018.9564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Wang W, Xing D, Song Y, Liu F. Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2018;97:e0164. [PMID: 29561425 DOI: 10.1097/MD.0000000000010164] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zhou XL, Yu CH, Wang WW, Ji FZ, Xiong YZ, Zhu WG, Tong YS. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021;16:94. [PMID: 34039375 DOI: 10.1186/s13014-021-01821-6] [Reference Citation Analysis]
8 Fang M, Song T, Liang X, Lv S, Li J, Xu H, Luo L, Jia Y. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:37080-90. [PMID: 28415745 DOI: 10.18632/oncotarget.16180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Ying J, Zhang M, Qiu X, Lu Y. The potential of herb medicines in the treatment of esophageal cancer. Biomed Pharmacother. 2018;103:381-390. [PMID: 29674273 DOI: 10.1016/j.biopha.2018.04.088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
10 Yoon DH, Jang G, Kim JH, Kim YH, Kim JY, Kim HR, Jung HY, Lee GH, Song HY, Cho KJ, Ryu JS, Kim SB. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2015;91:489-96. [PMID: 25680595 DOI: 10.1016/j.ijrobp.2014.11.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
11 Ojima T, Nakamura M, Nakamori M, Katsuda M, Hayata K, Maruoka S, Shimokawa T, Yamaue H. Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus. Oncology 2018;95:116-20. [DOI: 10.1159/000488861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Jiao Y, Shen Y, Yan H, Liu Y, Tan H, Li J. Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer. Pak J Med Sci 2016;32:1141-5. [PMID: 27882010 DOI: 10.12669/pjms.325.10632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Ojima T, Nakamura M, Nakamori M, Katsuda M, Hayata K, Kitadani J, Maruoka S, Shimokawa T, Yamaue H. Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. Oncotarget 2019;10:847-55. [PMID: 30783514 DOI: 10.18632/oncotarget.26614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Tomasello G, Ghidini M, Barni S, Passalacqua R, Petrelli F. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. Expert Rev Clin Pharmacol 2017;10:649-60. [PMID: 28349718 DOI: 10.1080/17512433.2017.1313112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Lu Z, Lu C, Li C, Jiao Y, Li Y, Zhang G. Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways. Mol Med Rep 2019;20:2091-100. [PMID: 31322237 DOI: 10.3892/mmr.2019.10474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ji Y, Du X, Tian Y, Sheng L, Cheng L, Chen Y, Qiu G, Zhou X, Bao W, Zhang D, Chen M. A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Oncotarget 2017;8:83022-9. [PMID: 29137320 DOI: 10.18632/oncotarget.20938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
17 Hou XF, Xu LP, Song HY, Li S, Wu C, Wang JF. ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNAWorld J Gastroenterol 2017; 23(10): 1796-1803 [PMID: 28348485 DOI: 10.3748/wjg.v23.i10.1796] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]